/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ENDRA Life Sciences Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$5.957 -0.0055(-0.55%) NDRA at 04 Dec 2025 04:39 PM Diagnostics & Research
Lowest Today 5.85
Highest Today 6.235
Today’s Open 5.87
Prev. Close 5.99
52 Week High 11.96
52 Week Low 2.90
Day’s Range: Low 5.85 High 6.235
52-Week Range: Low 2.90 High 11.96
1 day return -
1 Week return +1.66
1 month return +22.78
3 month return +43.29
6 month return +69.63
1 year return +14.68
3 year return +67.3
5 year return -63.75
10 year return -

Institutional Holdings

UBS Group AG 0.62

Fidelity Extended Market Index 0.51

Fidelity Series Total Market Index 0.09

Spartan Total Market Index Pool G 0.06

Vanguard Institutional Extnd Mkt Idx Tr 0.02

Northwestern Mutual Wealth Management Co 0.00

Spartan Extended Market Index Pool F 0.00

Bank of America Corp 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Morgan Stanley - Brokerage Accounts 0.00

Tower Research Capital LLC 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 8.97 M

PB Ratio 40.2245

PE Ratio 0.2977

Enterprise Value 6.62 M

Total Assets 4.45 M

Volume 51501

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:0 0.0M, FY20:null 0.0M, FY19:0 0.0M

Annual Net worth FY23:-11890310 -11.9M, FY22:-13200625 -13.2M, FY21:-11189705 -11.2M, FY20:-11966769 -12.0M, FY19:-15554530 -15.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:211600 0.2M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-39389 -0.0M, Q2/2025:-32790 -0.0M, Q1/2025:-45583 -0.0M, Q3/2024:null 0.0M, Q2/2024:-50124 -0.1M

Quarterly Net worth Q3/2025:-1595959 -1.6M, Q2/2025:-1225912 -1.2M, Q1/2025:-1036330 -1.0M, Q3/2024:-2354090 -2.4M, Q2/2024:-2229153 -2.2M

Fund house & investment objective

Company Information ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Organisation Diagnostics & Research

Employees 21

Industry Diagnostics & Research

CEO Mr. Alexander Y. Tokman

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow